In a recent study published in Annals of Internal Medicine, researchers at Johns Hopkins Bloomberg School of Public Health identified more than two decades of shortcomings in the approval of prescription opioids by the FDA. Researchers determined that there were no trials lasting longer than three months for products labeled for the treatment of chronic pain,, the trials often excluded patients who could not tolerate the drugs, and the trials completely failed to assess well-known opioid-related adverse events.